Hunter Syndrome Market analysis based on Epidemiology forecasting | Key Companies: Denali Therapeutics, Regenxbio, Homology Medicines, Takeda, etc.

March 23 21:26 2023
Hunter Syndrome Market analysis based on Epidemiology forecasting | Key Companies: Denali Therapeutics, Regenxbio, Homology Medicines, Takeda, etc.
DelveInsight Business Research LLP
DelveInsight’s ‘Hunter Syndrome -Market Insights, Epidemiology and Market Forecast– 2032’ report delivers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United States, EU4(Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s ‘Hunter Syndrome -Market Insights, Epidemiology and Market Forecast– 2032’ report delivers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United States, EU4(Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Hunter Syndrome also known as the MPS II market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Hunter Syndrome market size from 2017 to 2030. The report also covers current Hunter Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the Key Facts of the Hunter Syndrome Market Report:

  • The total diagnosed prevalent population of Hunter Syndrome in the 7 major markets was 1,173 in 2021.

  • In the case of Hunter Syndrome patients in the United States, the diagnosed prevalent cases were found to be 519 in 2021 which is anticipated to increase at a CAGR of 0.7% during the forecasted period. 

  • In Japan, the diagnosed prevalence of Hunter Syndrome was found to be 315 in 2021, resulting in the second highest after the US across the 7MM. 

  • In the EU5 countries, the diagnosed prevalence of Hunter Syndrome was maximum in Germany with 85 cases, followed by the United Kingdom with 69 cases in 2021. While, the least number of cases were found in Spain, in 2021. 

  • According to the findings of the National Institute of Health, MPS II is a progressively debilitating disorder that primarily affects males affecting different parts of the body. MPS II occurs in approximately 1 in 100,000–1 in 170,000 males in a population. Similar findings have been quoted by the National MPS Society and National Organization for Rare Disorders

 Key Benefits of the report:

The report covers the descriptive overview of Hunter Syndrome, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.

• Comprehensive insight has been provided into the Hunter Syndrome epidemiology and treatment.

• Additionally, an all-inclusive account of both the current and emerging therapies for Hunter Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of the Hunter Syndrome market; historical and forecasted is included in the report, covering the 7MM drug outreach.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Hunter Syndrome market.

Got queries? Click here to know more about the Hunter Syndrome Market Landscape

 

Hunter Syndrome Overview

Hunter syndrome is also known as Mucopolysaccharidosis type II (MPS II). It is a condition that affects many different parts of the body and mainly affects males. It is a progressive disorder, but the rate of progression varies among affected individuals. It is a rare, X-linked disorder caused due to a deficiency of the lysosomal enzyme iduronate-2-sulfatase, which plays a major role in the catabolism of glycosaminoglycans (GAG). 

Hunter Syndrome Epidemiological Segmentation 

  • Hunter Syndrome total diagnosed prevalent cases

  • Hunter Syndrome severity based diagnosed prevelant in the population 

Hunter Syndrome Market Outlook 

Treatments include enzyme replacement therapy along with the new upcoming therapeutic strategies that work on the principle of iduronate 2-sulfatase (I2S) enzyme replacement and gene therapies. The medical management for Hunter Syndrome comprises several aspects such as symptomatic treatment as well as prevention of secondary risks associated with Hunter Syndrome. The current 7MM possesses only one approved product namely Elaprase (idursulfase) to treat patients with Hunter Syndrome.

 Learn more by requesting for sample @ Hunter Syndrome Market Landscape

Hunter Syndrome Key Companies

  • Homology Medicines

  • Denali Therapeutics

  • Regenxbio

  • Takeda

  • And many others 

 Hunter Syndrome Therapies 

  • HMI-203

  • DNL310

  • RGX-121

  • SHP-609/ TAK-609 

  • And many others 

Hunter Syndrome Market Drivers 

  • Robust Pipeline Activity

  • Reimbursement of Elaprase 

  •  Increasing Awareness of Hunter Syndrome

 Hunter Syndrome Market Barriers 

  • Drawbacks of Elaprase 

  • High Cost of Therapy 

  •  Adverse Events of Current Treatment Options 

 

Read more: Hunter Syndrome Market Trends 

 Table of Contents

  •  Key Insights 

  •  Report Introduction 

  •  Executive Summary of Hunter Syndrome 

  •  Hunter Syndrome Disease Background and Overview

  •  Hunter Syndrome Epidemiology and patient population

  •  Hunter Syndrome Emerging Therapies

  •  Hunter Syndrome Market Outlook

  •  Hunter SyndromeMarket Access and Reimbursement of Therapies

  •  Appendix

  •  Hunter Syndrome Report Methodology

  •  DelveInsight Capabilities

  •  Disclaimer

  •  About DelveInsight

Click here to read more about Hunter Syndrome market 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

  Categories: